[go: up one dir, main page]

WO1992011259A1 - Amides azabicycliques ou esters d'acides benzoïques halogenes - Google Patents

Amides azabicycliques ou esters d'acides benzoïques halogenes Download PDF

Info

Publication number
WO1992011259A1
WO1992011259A1 PCT/GB1991/002210 GB9102210W WO9211259A1 WO 1992011259 A1 WO1992011259 A1 WO 1992011259A1 GB 9102210 W GB9102210 W GB 9102210W WO 9211259 A1 WO9211259 A1 WO 9211259A1
Authority
WO
WIPO (PCT)
Prior art keywords
compound according
compound
formula
chloro
pharmaceutically acceptable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/GB1991/002210
Other languages
English (en)
Inventor
Francis David King
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Beecham Group PLC
Original Assignee
Beecham Group PLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Beecham Group PLC filed Critical Beecham Group PLC
Priority to JP4501723A priority Critical patent/JPH06503332A/ja
Publication of WO1992011259A1 publication Critical patent/WO1992011259A1/fr
Priority to KR1019930701884A priority patent/KR930703308A/ko
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D451/00—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
    • C07D451/02—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof
    • C07D451/04—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof with hetero atoms directly attached in position 3 of the 8-azabicyclo [3.2.1] octane or in position 7 of the 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D451/00—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
    • C07D451/14—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing 9-azabicyclo [3.3.1] nonane ring systems, e.g. granatane, 2-aza-adamantane; Cyclic acetals thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D453/00—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids
    • C07D453/02—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids containing not further condensed quinuclidine ring systems

Definitions

  • This invention relates to novel, compounds having pharmacological activity, to a process for their preparation and their use as pharmaceuticals.
  • EP-A-220011 (Beecham Group p.I.e.) describes the use of a benzamide derivative, as a 5-HT receptor antagonist.
  • the present invention provides a compound of formula (I), or a pharmaceutically acceptable salt thereof:
  • R* is hydrogen or C-*__g al oxy
  • R2 is halo
  • R3 is halo
  • L is 0 or NH
  • Z is a di-azacyclic or azabicyclic side chain; having 5-HT3 receptor antagonist activity.
  • Suitable examples of alkyl moieties in R- ⁇ include methyl, ethyl, n- and iso-propyl, n.-, iso-, sec- and tert-butyl.
  • Suitable examples of halo moieties include fluoro, chloro and bromo.
  • R- ⁇ is hydrogen, R2 is chloro and R3 is chloro; or R ⁇ _ is methoxy, R 2 is fluoro or chloro and R3 is chloro.
  • R is hydrogen or methyl; and X is oxygen, sulphur or nitrogen optionally substituted by C- ⁇ .g alkyl, C 3 _ 8 cycloalkyl, C3_g cycloalkyl C 1-4 alkyl, phenyl, naphthyl, phenyl C* j __ 4 alkyl or naphthyl ⁇ - alkyl wherein a phenyl c: naphthyl moiety is optionally substituted by one or more of halo, C"L_g alkoxy or ⁇ __- Q alkyl.
  • Side chains Z of particular interest include tropane, oxagranatane and azagranatane, where R is methyl.
  • Suitable values for N-substituents when X is N are as described in PCT/GB91/01629, for example, iso-propyl or ethyl.
  • L is preferably NK.
  • COL in formula (I) may be replaced by a bioisostere therefor, for example, 1,2,4-oxadiazole and the other groups of structure h) described in EP-A-377967 (Beecham Group p.I.e.).
  • the pharmaceutically acceptable salts of the compounds of the formula (I) include acid addition salts with conventional acids such as hydrochloric, hydrobromic, boric, phosphoric, sulphuric acids and pharmaceutically acceptable organic acids such as acetic, tartaric, maleic, citric, succinic, benzoic, ascorbic, methanesulphonic, ⁇ -keto glutaric, ⁇ -glycerophosphoric, and glucose-1-phosphoric acids.
  • conventional acids such as hydrochloric, hydrobromic, boric, phosphoric, sulphuric acids
  • pharmaceutically acceptable organic acids such as acetic, tartaric, maleic, citric, succinic, benzoic, ascorbic, methanesulphonic, ⁇ -keto glutaric, ⁇ -glycerophosphoric, and glucose-1-phosphoric acids.
  • Examples of pharmaceutically acceptable salts include quaternary derivatives of the compounds of formula (I) such as the compounds quaternised by compounds R ⁇ -T wherein R ⁇ is C*_g alkyl, phenyl-C- ⁇ .g alkyl or C ⁇ _ 7 cycloalkyl, and T is a radical corresponding to an anion of an acid.
  • R ⁇ include methyl, ethyl and n- and iso-propyl; and benzyl and phenethyl.
  • Suitable examples of T include halide such as chloride, bromide and iodide.
  • Examples of pharmaceutically acceptable salts also include internal salts such as N-oxides.
  • the compounds of the formula (I) may also form pharmaceutically acceptable solvates, such as hydrates, which are included wherever a compound of formula (I) or a salt thereof is herein referred to.
  • the invention also provides a process for the preparation of a compound of formula (I) , or a pharmaceutically acceptable salt thereof, which process comprises reacting a compound of formula (II) :
  • R ] , R R 3' an oYor Z' are R- ⁇ , R 2 , R3 and/or Z respectively or groups or atoms, convertible thereto;
  • R 4 is hydrogen or an N-protecting group;
  • Q* ⁇ is a leaving group; 10 and the remaining variables are as hereinbefore defined; and thereafter optionally converting R ⁇ ', R 2 ' , R3' and/or Z' to another group or atom R- j _, R 2 , R3 or Z; and optionally forming a pharmaceutically acceptable salt of the resultant compound of formula (I) .
  • R 4 when other than hydrogen, include ⁇ -, -I Q acyl such as alkanoyl, wherein the alkyl may be as listed for R-_ , preferably acetyl.
  • R_. is usually hydrogen. 0
  • Examples of leaving groups Q- ⁇ , displaceable by a nucleophile include halogen such as chloro and bromo, hydroxy, -__ ⁇ alkoxy, such as CH3O and C 2 Hc;0-, PhO-, activated hydrocarbyloxy, such as Cl ⁇ CgO- or C1 C0-; or 5 COQ-j , forms a mixed anhydride, so that Q* ⁇ is carboxylic acyloxy; or a nitrogen-linked heterocycle, such as imidazole.
  • a group Q* ⁇ is a halide, or C0Q*-_, forms a mixed anhydride, 0 then the reaction is preferably carried out at non-extreme temperatures in an inert non-hydroxylic solvent, such as • benzene, dichloromethane, toluene, diethyl ether, tetrahydrofuran (THF) or dimethylformamide (DMF) . It is also preferably carried out in the presence of an acid 5 acceptor, such as an organic base, in particular a tertiary amine, such as triethylamine, trimethylamine, pyridine or picoline, some of which can also function as the solvent. Alternatively, the acid acceptor can be inorganic, such as calcium carbonate, sodium carbonate or potassium carbonate. Temperatures of 0°-100°C, in particular 10-80°C are suitable.
  • an inert non-hydroxylic solvent such as • benzene, dichloromethane, toluene, diethy
  • a group Q- ⁇ is C 1-4 alkoxy, phenoxy or activated hydrocarbyloxy then the reaction is preferably carried out in an inert polar solvent, such as toluene or dimethylformamide. It is also preferred that the group Q**_ is CI3CO- and that the reaction is carried out in toluene at reflux temperature.
  • a group Q* j _ is hydroxy
  • the reaction is generally carried out in an inert non-hydroxylic solvent, such as dichloromethane, THF or D F optionally in the presence of a dehydrating agent such as a carbodiimide, for example dicyclohexylcarbodiimide.
  • a dehydrating agent such as a carbodiimide, for example dicyclohexylcarbodiimide.
  • the reaction may be carried out at any non-extreme temperature, such as -10 to 100°C, for example, 0 to 80°C. Generally, higher reaction temperatures are employed with less active compounds whereas lower temperatures are employed with the more active compounds.
  • acyloxy leaving groups include C 1-4 alkanoyloxy and C1- alkoxycarbonyloxy, in which case the reaction is preferably carried out in an inert solvent, such as dichloromethane, at a non-extreme temperature for example ambient temperatures in the presence of an acid acceptor, such as triethylamine.
  • C* ] __4 alkoxycarbonyloxy leaving groups may be generated in situ by treatment of the corresponding compound wherein Q**_ is hydroxy with a C 1-4 alkyl chloroformate.
  • a group Q* ⁇ is activated hydrocarbyloxy then the reaction is preferably carried out in an inert polar solvent, such as dimethylformamide. It ' is also.preferred that the activated hydrocarbyloxy group is a pentachlorophenyl ester and that the reaction is carried out at ambient temperature.
  • the compound of formula (III) may be in the form of a reactive derivative thereof, which is often a salt, such as the lithium, sodium or potassium salt.
  • R 2 ' or R ' group which is convertible R 2 or R include a hydrogen substituent which is convertible to a halogen substituent by halogenation using conventional halogenating agents.
  • Z' when other than Z may be wherein R is replaced by R' which is a hydrogenolysable protecting group which is benzyl optionally substituted by one or two groups selected from halo, C 1-4 alkoxy and C-__ ⁇ alkyl.
  • R' which is a hydrogenolysable protecting group which is benzyl optionally substituted by one or two groups selected from halo, C 1-4 alkoxy and C-__ ⁇ alkyl.
  • Such benzyl groups may, for example, be removed, when R 1 /R 2 is not halogen, by conventional transition metal catalysed hydrogenolysis to give compounds of the formula (I) wherein R is hydrogen.
  • This invention also provides a further process for the preparation of a compound of the formula (I) wherein R is methyl or a pharmaceutically acceptable salt thereof, which comprises N-methylating a compound of formula (I) wherein R is hyirogen, and optionally forming a pharmaceutically acceptable salt of the resulting compound of the formula (I) .
  • a further process for the preparation of a compound of the formula (I) wherein R is methyl or a pharmaceutically acceptable salt thereof which comprises N-methylating a compound of formula (I) wherein R is hyirogen, and optionally forming a pharmaceutically acceptable salt of the resulting compound of the formula (I) .
  • 'N-methylation' may be achieved by reaction with a compound CH Q 2 wherein Q 2 is a leaving group.
  • Suitable values for Q 2 include groups displaced by nucleophils such as Cl, Br, I, OS0 2 CH 3 or OSO ⁇ H ⁇ pC ⁇ , preferably Cl, Br or I.
  • the reaction may be carried out. under conventional alkylation conditions for example in an inert solvent such as dimethylformamide in the presence of an acid acceptor such as potassium carbonate. Generally the reaction is carried out at non-extreme temperature such as at ambient cr slightly above.
  • 'N-methylation' may be effected under conventional reductive alkylation conditions.
  • Interconverting R in the compound of the formula (III) before coupling with the compound of the formula (II) is also possible. Such interconversions are effected conveniently under the above conditions. It is desirable to protect any amine function with a group readily removable by acidolysis such as a C 2 _ 7 alkanoyl group, before R/Z interconversion.
  • the benzoic acid derivative intermediates of formula (II) are known or are preparable analogously to, or routinely from, known compounds.
  • R 2 is fluoro
  • the intermediate may be prepared by fluorination of the corresponding R is hydrogen compound, using a suitable fluorinating catalyst, such as trifluoromethyl hypofluorite, as described in Description 1 hereinafter.
  • Compounds of the formula (III) are generally prepared from the corresponding exocyclic keto derivative of the azabicyclic side chain, prepared by condensation methods, often using a substituted piperidine. They may be prepared by processes described in the aforementioned Patent Publications relating to values of the side chain Z.
  • the -COL- linkage has an endo orientation with respect to the ring of the bicyclic moiety to which it is attached.
  • a mixture of endo and ⁇ xo isomers of the compound of the formula (I) may be synthesised non-stereospecifically and the desired iso er separated conventionally therefrom e.g. by chromatography; or alternatively the endo isomer may if desired by synthesised from the corresponding endo form of the compound of the formula (II) .
  • Corresponding geometric isomeric pairs are possible for the isoquinuclidine, isogranatane, oxa/thia-isogranatane and isotropane side chains.
  • compositions of this invention may be formed conventionally.
  • the salts may be formed for example by reaction of the base compound of formula (I) with a pharmaceutically acceptable organic or inorganic acid.
  • the compounds of the present invention are 5-HT3 receptor antagonists and it is thus believed may generally be used in the treatment or prophylaxis of pain, emesis, CNS disorders and gastrointestinal disorders.
  • Pain includes migraine, cluster headache, trigeminal neuralgia and visceral pain; emesis, includes, in particular, that of preventing vomiting and nausea associated with cancer therapy, post-operative emesis, and nausea associated with migraine.
  • cancer therapy included.e that using .cytotoxic agents, such as platinum complexes including cisplatin, and also doxorubicin and cyclophosphamide, particularly cisplatin; and also radiation treatment.
  • CNS disorders include anxiety, psychosis, cognitive disorders such as senile dementia and age associated memory impairment (AAMI) , and drug dependence.
  • Gastrointestinal disorders include irritable bowel syndrome and diarrohea.
  • 5-HT3 receptor antagonists may also be of potential use in the treatment of obesity, arrhythmia, and/or disorders associated with myocardial instability.
  • the invention also provides a pharmaceutical composition
  • a pharmaceutical composition comprising a compound of formula (I) , or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.
  • compositions are prepared by admixture and are usually adapted for oral or parenteral administration, and as such may be in the form of tablets, capsules, oral liquid preparations, powders, granules, lozenges, reconstitutable powders, injectable and infusable solutions or suspensions or suppositories. Orally administrable compositions are preferred, since they are more convenient for general use.
  • Tablets and capsules for oral administration are usually presented in a unit dose, and contain conventional excipiehts such as binding agents, fillers, diluents, tabletting agents, lubricants, disintegrants, colourants, flavourings, and wetting agents.
  • the tablets may be coated according to well known methods in the art, for example with an enteric coating.
  • Suitable fillers for use include cellulose, mannitol, lactose and other similar agents.
  • Suitable disintegrants include starch, polyvinylpolypyrrolidone and starch derivatives such as sodium starch glycollate.
  • Suitable lubricants include, for example, magnesium stearate.
  • Suitable pharmaceutically acceptable wetting agents include sodium lauryl sulphate.
  • Oral liquid preparations may be in the form of, for example, aqueous or oily suspensions, solutions, emulsions, syrups, or elixirs, or may be presented as a dry product for reconstitution with water or other suitable vehicle before use. Such liquid preparations may.
  • suspending agents for example sorbitol, syrup, methyl cellulose, gelatin, hydroxyethylcellulose, carboxymethylcellulose, aluminium stearate gel or hydrogenated edible fats, emulsifying agents, for example lecithin, sorbitan onooleate, or acacia
  • non-aqueous vehicles which may include edible oils
  • preservatives for example methyl or propyl p-hydroxybenzoate or sorbic acid, and if desired conventional flavouring or colouring agents.
  • Oral liquid preparations are usually in the form of aqueous or oily suspensions, solutions, emulsions, syrups, or elixirs or are presented as a dry product for reconstitution with water or other suitable vehicle before use.
  • Such liquid preparations may contain conventional additives such as suspending agents, emulsifying agents, non-aqueous vehicles (which may include edible oils) , preservatives, and flavouring or colouring agents.
  • the oral compositions may be prepared by conventional methods of blending, filling or tabletting. Repeated blending operations may be used to distribute the active agent throughout those compositions employing large quantities of fillers. Such operations are, of course, conventional in the art.
  • fluid unit dose forms are prepared containing a compound of the present invention and a sterile vehicle.
  • the compound depending on the vehicle and the concentration, can be either suspended or dissolved.
  • Parenteral solutions are normally prepared by dissolving the compound in a vehicle and filter sterilising before filling into a suitable vial or ampoule and sealing.
  • adjuvants such as a local anaesthetic, preservatives and buffering agents are also dissolved in the vehicle.
  • the composition can be frozen after filling into the vial and the water removed under vacuum.
  • Parenteral suspensions are prepared in substantially the same manner except that the compound is suspended in the vehicle instead of being dissolved and sterilised by exposure of ethylene oxide before suspending in the sterile vehicle.
  • a surfactant or wetting agent is included in the composition to facilitate uniform distribution of the compound of the invention.
  • the invention further provides a method of treatment or prophylaxis of pain, emesis, CNS disorders and/or gastrointestinal disorders in mammals, such as humans, which comprises the administration of an effective amount of a compound of the formula (I) or a pharmaceutically acceptable salt thereof.
  • a unit dose for a 70kg adult will normally contain 0.05 to lOOOmg for example 0.5 to 500mg, of the compound of the invention.
  • Unit doses may be administered once or more than once a day, for example, 2, 3 or 4 times a day, more usually 1 to 3 times a day, that is in the range of approximately 0.0001 to.50mg/kg/day, more usually 0.0002 to 25 mg/kg/day.
  • the invention also provides a compound of formula (I) or a pharmaceutically acceptable salt thereof for use as an active therapeutic substance, in particular for use in the treatment of pain, emesis, CNS disorders and/or gastrointestinal disorders.
  • Methyl-4-acetamido-5-chloro-2-methoxy benzoate (10.9g) was dissolved in chloroform (40 ml), cooled to -10°C under • nitrogen. A three molar excess of trifluoromethyl hypofluorite was slowly bubbled through the stirred, cooled solution for 6 hours. A slow positive nitrogen stream was maintained throughout the reaction. After warming to room temperature and thoroughly purging with nitrogen, the chloroform was removed in vacuo.
  • Methyl-4-acetamido-5-chloro-3-fluoro-2-methoxybenzoate (1.89g) in 25 ml ethanol was treated with a solution of sodium hydroxide (1.15g) in 15 ml water. 'The mixture was heated under reflux for 16 hours then cooled. The solvent was removed in vacuo and the residue acidified. The precipitated solid was collected by filtration to give 1.48g product.
  • the title compound was prepared from 4-amino-5-chloro-3- fluoro-2-methoxybenzoic acid via an analagous procedure to that described for Example 1.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

On décrit des composés de formule (I) dans laquelle Z représente une chaîne latérale di-azacyclique ou azabicyclique, lesdits composés présentant une activité inhibitrice des récepteurs 5-HT3.
PCT/GB1991/002210 1990-12-19 1991-12-12 Amides azabicycliques ou esters d'acides benzoïques halogenes Ceased WO1992011259A1 (fr)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP4501723A JPH06503332A (ja) 1990-12-19 1991-12-12 ハロゲン化安息香酸のアザ二環式アミドまたはエステル
KR1019930701884A KR930703308A (ko) 1990-12-19 1993-06-18 할로겐화 벤조산의 아자비시클릭 아미드 또는 에스테르

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB9027487.9 1990-12-19
GB909027487A GB9027487D0 (en) 1990-12-19 1990-12-19 Pharmaceuticals

Publications (1)

Publication Number Publication Date
WO1992011259A1 true WO1992011259A1 (fr) 1992-07-09

Family

ID=10687217

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/GB1991/002210 Ceased WO1992011259A1 (fr) 1990-12-19 1991-12-12 Amides azabicycliques ou esters d'acides benzoïques halogenes

Country Status (13)

Country Link
EP (1) EP0563087A1 (fr)
JP (1) JPH06503332A (fr)
KR (1) KR930703308A (fr)
AU (1) AU9053391A (fr)
CA (1) CA2098729A1 (fr)
GB (1) GB9027487D0 (fr)
IE (1) IE914395A1 (fr)
MX (1) MX9102630A (fr)
NZ (1) NZ241019A (fr)
PT (1) PT99831A (fr)
TW (1) TW226020B (fr)
WO (1) WO1992011259A1 (fr)
ZA (1) ZA919884B (fr)

Cited By (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994001095A3 (fr) * 1992-07-03 1994-04-14 Smithkline Beecham Plc Medicaments pour le traitement de douleurs viscerales et de migraines
WO1999017755A3 (fr) * 1997-10-07 1999-09-23 Glaxo Group Ltd Medicaments
WO2002016356A3 (fr) * 2000-08-18 2002-05-16 Upjohn Co Composes aryle substitues par quinuclidine destines au traitement de maladies
WO2002016357A3 (fr) * 2000-08-18 2002-05-30 Upjohn Co Composes aryle substitues par quinuclidine destines au traitement de maladies
WO2002016358A3 (fr) * 2000-08-18 2002-07-18 Upjohn Co Composes aryliques substitues par quinuclidine destines au traitement de maladies
US6492385B2 (en) 2000-08-18 2002-12-10 Pharmacia & Upjohn Company Quinuclidine-substituted heteroaryl moieties for treatment of disease
US6500840B2 (en) 2000-08-21 2002-12-31 Pharmacia & Upjohn Company Quinuclidine-substituted heteroaryl moieties for treatment of disease
US6599916B2 (en) 2000-08-21 2003-07-29 Pharmacia & Upjohn Company Quinuclidine-substituted heteroaryl moieties for treatment of disease
US6852716B2 (en) 2002-02-15 2005-02-08 Pfizer Inc Substituted-aryl compounds for treatment of disease
US6869946B2 (en) 2001-04-19 2005-03-22 Pfizer Inc Substituted azabicyclic moieties for the treatment of disease
US7176198B2 (en) 2002-08-01 2007-02-13 Pfizer Inc. 1H-pyrazole and 1H-pyrrole-azabicyclic compounds for the treatment of disease

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW200842733A (en) 2007-04-17 2008-11-01 Univ Nat Chiao Tung Object image detection method

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3001328A1 (de) * 1979-01-16 1980-07-24 Delalande Sa Neue nortropan-derivate, verfahren zu ihrer herstellung und diese derivate enthaltende arzneimittel
EP0099789A1 (fr) * 1982-07-02 1984-02-01 Delalande S.A. Nouveaux dérivés de l'amino-3 quinuclidine, leur procédé de préperation et leur application en thérapeutique
EP0220011A2 (fr) * 1985-10-12 1987-04-29 Beecham Group Plc Utilisation des azabicycloalkylbenzamides pour le traitement des maladies de la motilité gastro-intestinale, migraine, émésis, céphalalgie de la migraine, neuralgie trigéminale et arrhythmie
EP0377967A2 (fr) * 1988-12-13 1990-07-18 Beecham Group Plc Dérivés du 9-aza-3-(oxa/thia)-bicyclo[3,2,1]nonane, procédé et intermédiaires pour leur préparation et compositions pharmaceutiques les contenant

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3001328A1 (de) * 1979-01-16 1980-07-24 Delalande Sa Neue nortropan-derivate, verfahren zu ihrer herstellung und diese derivate enthaltende arzneimittel
EP0099789A1 (fr) * 1982-07-02 1984-02-01 Delalande S.A. Nouveaux dérivés de l'amino-3 quinuclidine, leur procédé de préperation et leur application en thérapeutique
EP0220011A2 (fr) * 1985-10-12 1987-04-29 Beecham Group Plc Utilisation des azabicycloalkylbenzamides pour le traitement des maladies de la motilité gastro-intestinale, migraine, émésis, céphalalgie de la migraine, neuralgie trigéminale et arrhythmie
EP0377967A2 (fr) * 1988-12-13 1990-07-18 Beecham Group Plc Dérivés du 9-aza-3-(oxa/thia)-bicyclo[3,2,1]nonane, procédé et intermédiaires pour leur préparation et compositions pharmaceutiques les contenant

Cited By (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994001095A3 (fr) * 1992-07-03 1994-04-14 Smithkline Beecham Plc Medicaments pour le traitement de douleurs viscerales et de migraines
US6429209B2 (en) 1997-10-07 2002-08-06 Smithkline Beecham Corporation Methods for treating irritable bowel syndrome
WO1999017755A3 (fr) * 1997-10-07 1999-09-23 Glaxo Group Ltd Medicaments
US6284770B1 (en) 1997-10-07 2001-09-04 Glaxo Wellcome Inc. Medicaments for the treatment of non-constipated female irritable bowel syndrome
US6593336B2 (en) 1997-10-07 2003-07-15 Smithkline Beecham Corporation Methods for treating irritable bowel syndrome
US6486172B2 (en) 2000-08-18 2002-11-26 Pharmacia & Upjohn Company Quinuclidine-substituted aryl compounds for treatment of disease
WO2002016358A3 (fr) * 2000-08-18 2002-07-18 Upjohn Co Composes aryliques substitues par quinuclidine destines au traitement de maladies
US6479510B2 (en) 2000-08-18 2002-11-12 Pharmacia & Upjohn Company Quinuclidine-substituted aryl compounds for treatment of disease
WO2002016357A3 (fr) * 2000-08-18 2002-05-30 Upjohn Co Composes aryle substitues par quinuclidine destines au traitement de maladies
US6492385B2 (en) 2000-08-18 2002-12-10 Pharmacia & Upjohn Company Quinuclidine-substituted heteroaryl moieties for treatment of disease
WO2002016356A3 (fr) * 2000-08-18 2002-05-16 Upjohn Co Composes aryle substitues par quinuclidine destines au traitement de maladies
US6500840B2 (en) 2000-08-21 2002-12-31 Pharmacia & Upjohn Company Quinuclidine-substituted heteroaryl moieties for treatment of disease
US6599916B2 (en) 2000-08-21 2003-07-29 Pharmacia & Upjohn Company Quinuclidine-substituted heteroaryl moieties for treatment of disease
US6869946B2 (en) 2001-04-19 2005-03-22 Pfizer Inc Substituted azabicyclic moieties for the treatment of disease
US6852716B2 (en) 2002-02-15 2005-02-08 Pfizer Inc Substituted-aryl compounds for treatment of disease
US7176198B2 (en) 2002-08-01 2007-02-13 Pfizer Inc. 1H-pyrazole and 1H-pyrrole-azabicyclic compounds for the treatment of disease

Also Published As

Publication number Publication date
ZA919884B (en) 1992-10-28
AU9053391A (en) 1992-07-22
KR930703308A (ko) 1993-11-29
GB9027487D0 (en) 1991-02-06
IE914395A1 (en) 1992-07-01
MX9102630A (es) 1992-06-01
NZ241019A (en) 1994-07-26
EP0563087A1 (fr) 1993-10-06
JPH06503332A (ja) 1994-04-14
PT99831A (pt) 1992-12-31
TW226020B (fr) 1994-07-01
CA2098729A1 (fr) 1992-06-20

Similar Documents

Publication Publication Date Title
EP0315390B1 (fr) Composés nouveaux de 4-oxobenzotriazine et 4-oxoquinazoline
EP0200444B1 (fr) Azabicyclononyl-indazole carboxamide ayant une activité antagoniste de la 5-HT
EP0255297B1 (fr) Composés azabicycliques, procédé pour leur préparation et leur utilisation pharmaceutique
US4937247A (en) 1-acyl indazoles
IE911399A1 (en) Novel compounds
AU626614B2 (en) 9-aza-3(oxa or thio)bicyclo(3.3.1)nonane derivatives
EP0223385B1 (fr) 8-Azabicyclo[3,2,1]octane et 9-azabicyclo[3,3,1]nonane dérivés
EP0254584B1 (fr) Composés azabicycliques, procédé pour leur préparation et leur utilisation pharmaceutique
IE60111B1 (en) Indole derivatives having an azabicyclic side chain, process for their preparation, intermediates, and pharmaceutical compositions
EP0289170A2 (fr) Composés azabicycliques, leur procédé de préparation et compositions pharmaceutiques les contenant
EP0261964A2 (fr) Composes azacycliques utilises comme antagonistes du recepteur 5-ht3
WO1992011259A1 (fr) Amides azabicycliques ou esters d&#39;acides benzoïques halogenes
CA2091375A1 (fr) Derives de l&#39;acide cinnoline-3-carboxylique
US5726187A (en) N-alkylpiperidinyl-4-methyl carboxylic esters/amides of condensed ring systems as 5-HT4 receptor antagonists
WO1993008185A1 (fr) N-aryle-n1-azabicyclo-urees utilisees comme antagonistes de 5-ht3
WO1989009217A1 (fr) Nouveaux composes
AU651645B2 (en) Pharmaceuticals
US5322951A (en) Certain 1-(2,3-dihydro-indole)carbonyl intermediates
WO1991001316A1 (fr) Nouveau derive de 9-azabicyclo[3.3.1] nonane
WO1993008186A1 (fr) Amides ou esters d&#39;acide pyridine-3-carboxylique utilises comme antagonistes de 5-ht¿3?
AU7609894A (en) Condensed indole derivatives as 5-ht4-receptor antagonists

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AU CA JP KR US

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FR GB GR IT LU MC NL SE

WWE Wipo information: entry into national phase

Ref document number: 1992900452

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2098729

Country of ref document: CA

WWP Wipo information: published in national office

Ref document number: 1992900452

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 1992900452

Country of ref document: EP